ubamatamab + pegylated liposomal doxorubicin

**Ubamatamab + pegylated liposomal doxorubicin** is a combination drug regimen composed of ubamatamab, an investigational bispecific monoclonal antibody (often referred to as a T-cell engager), and pegylated liposomal doxorubicin, a cytotoxic anthracycline anticancer agent encapsulated in polyethylene glycol (PEG)-coated liposomes. Ubamatamab targets both the tumor-associated antigen MUC16 (CA-125) present on ovarian and other cancers, and CD3 on T-cells, redirecting T-cell cytotoxicity against cancer cells. Pegylated liposomal doxorubicin is a formulation designed to prolong circulation time and enhance drug accumulation at tumor sites via the enhanced permeability and retention effect. Its mechanism involves inhibiting topoisomerase 2, thereby preventing DNA replication and promoting apoptosis in cancer cells[1][7]. The combination is primarily under investigation for use in patients with ovarian cancer, leveraging the immunotherapeutic function of ubamatamab and the cytotoxic action of pegylated liposomal doxorubicin.

Other names

PLDDoxil